Literature DB >> 3539304

Hurthle cell thyroid tumors. An immunohistochemical study.

T L Johnson, R V Lloyd, R E Burney, N W Thompson.   

Abstract

Twenty-three Hurthle cell neoplasms of the thyroid were analyzed immunohistochemically for thyroglobulin, carcinoembryonic antigen (CEA), and for immunoreactivity with a monoclonal antibody to p21 ras oncogene product. Both benign and malignant tumors defined by the presence or absence of invasion and metastasis stained positively for thyroglobulin. Most tumors expressed both CEA and p21 ras oncogene product. Clinicopathologic analysis showed that malignant tumors were larger, occurred in slightly older patients (mean age, 52.8 years), and had an almost equal sex distribution, whereas benign tumors were more common in women and occurred in younger patients (mean age, 44.7 years). These results indicate that both benign and malignant Hurthle cell thyroid tumors produce thyroglobulin and express both CEA and p21 ras oncogene product, whereas adjacent normal thyroid tissues showed weak to absent immunoreactivity for p21 ras oncogene product. Because there are no specific immunohistochemical markers to distinguish between benign and malignant Hurthle cell tumors, one needs to rely on traditional histologic features such as invasion and metastasis to distinguish between benign and malignant Hurthle cell neoplasms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3539304     DOI: 10.1002/1097-0142(19870101)59:1<107::aid-cncr2820590123>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

Review 2.  Benign Hürthle cell tumors of the thyroid: a diagnosis to be trusted?

Authors:  C S Grant; D Barr; J R Goellner; I D Hay
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

Review 3.  The utility of some modern techniques in understanding thyroid pathology.

Authors:  Virginia A LiVoisi
Journal:  Endocr Pathol       Date:  1990-06       Impact factor: 3.943

Review 4.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

5.  Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid.

Authors:  J J Ryan; I D Hay; C S Grant; L M Rainwater; G M Farrow; J R Goellner
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

6.  Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.

Authors:  Shuting Bai; Zubair W Baloch; Teresa D Samulski; Kathleen T Montone; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

7.  Hürthle cells predict hypothyroidism in interferon-γ transgenic mice of different genetic backgrounds.

Authors:  Shintaro Iwama; Alessandra De Remigis; Justin A Bishop; Hiroaki J Kimura; Patrizio Caturegli
Journal:  Endocrinology       Date:  2012-06-19       Impact factor: 4.736

8.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

Review 9.  My approach to oncocytic tumours of the thyroid.

Authors:  S L Asa
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

10.  Proliferative activity of oxyphilic (Hurthle) cells in reactive and neoplastic thyroid lersions.

Authors:  M S Tretiakova; M Papotti; G Bussolati
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.